Galapagos receives transparency notification from Wellington Management Group LLP
December 22 2015 - 4:07PM
Galapagos NV (Euronext:GLPG) (NASDAQ:GLPG)
received a
transparency notification from Wellington Management Group LLP.
Pursuant to Belgian transparency legislation1,
Galapagos received a transparency notification on 17 December 2015
from Wellington Management Group LLP, who notified that, as a
result of an acquisition of shares, since 3 December 2015, its
entirely-controlled subsidiary Wellington Management Company LLP
held 1,989,368 shares, representing 5.1% of the current 39,076,342
outstanding Galapagos shares. Wellington Management Group LLC
thus crossed a 5% threshold of Galapagos' voting rights. This
is the first transparency notice received from Wellington
Management Group LLP. The full transparency notice is
available for viewing on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is
a clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action. Our pipeline comprises three Phase 2, three Phase 1,
five pre-clinical, and 20 discovery studies in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications.
We are focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos
group, including fee-for-service subsidiary Fidelta, has
approximately 400 employees, operating from its Mechelen, Belgium
headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Forward-looking statements
This release may contain forward-looking statements.
Galapagos cautions the reader that forward-looking statements are
not guarantees of future performance. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition
and liquidity, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or
future results, financial conditions and liquidity, performance or
achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos' results,
performance, financial condition and liquidity, and the development
of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of result s
or developments in future periods. Among the factors that may
result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements.
A further list and description of these risks, uncertainties and
other risks can be found in Galapagos' Securities and Exchange
Commission (SEC) filings and reports, including in Galapagos'
prospectus filed with the SEC on 14 May 2015 and subsequent filings
and reports filed by Galapagos with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market
HUG#1975486
CONTACT: Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
Tel: +1 781 460 1784
E-mail: ir@glpg.com
Media:
Evelyn Fox
Director Communications
Tel: +31 6 53 591 999
E-mail: communications@glpg.com
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024